Protalex Inc

Protalex — IPO Roadshow (July 2016)

26 slides from Protalex's IPO roadshow presentation, Jul 6, 2016

  1. Slide 1: Investor Presentation July 2016

    Investor Presentation July 2016

  2. Slide 2: Disclaimer/Forward Looking Statements

    Disclaimer DISCLAIMER/FORWARD LOOKING STATEMENTS This presentation highlights certain information about Protalex , Inc. (the “Company”). Statements made in this presentation stating the Company’s beliefs, intentions, and expectations are forward - looking statements. The Company’s actual results cou

  3. Slide 3: Offering Summary

    Offering Summary 3 Issuer: Protalex , Inc. Ticker: PRTX (OTC >> Nasdaq ) Total amount offered: $10.0 million Over - allotment option: 15% Use of proceeds: R&D, working capital , pay a portion of accrued interest on outstanding notes, and general corporate purposes Bookrunner : Chardan

  4. Slide 4: Key Investment Highlights

    Key Investment Highlights ▪ Immune thrombocytopenia (ITP) (>$1B) ▪ Rheumatoid Arthritis (RA) (>$22B) ▪ Other autoimmune diseases ($Bs) 4 ▪ Experienced management ▪ Strong scientific advisors ▪ Low - burn model ▪ Funded - to - date by majority shareholder, Niobe Ventures, LLC ▪ Highly - purified biol

  5. Slide 5: Our Leadership Team

    Our Leadership Team  Arnold P. Kling – President; Director; Principal of Niobe Ventures, LLC, experienced investor in and manager of early stage technology companies  James W. Dowe III – Vice - Chair of SAB; active investor in biotechnology, computer software and investment management companies 

  6. Slide 6: Investment Thesis

    Investment Thesis  PRTX - 100 is a novel immunomodulatory compound with potential across various autoimmune indications ▪ ITP – an orphan disease ▪ RA – the largest autoimmune market ▪ Potential efficacy in a number of other orphan indications  Six clinical studies conducted to date, each demonstr

  7. Slide 7: Staphylococcal Protein A (SpA) and the Rationale for S. aureus-derived therapy

     Staphylococcus aureus ( S. aureus ) is a leading cause of blood - stream, bone, skin, soft tissue, pulmonary and device - related infections 1  In humans, the S. aureus bacterium does not elicit a protective immune response and patients often suffer from chronic or recurrent infections 2  S. aur

  8. Slide 8: Proposed Mechanisms of Action

    PRTX - 100: Proposed Mechanisms of Action  PRTX - 100: ▪ Modulates B - cells directly through their cell surface expression of a VH3 B - cell receptor ▪ Modulates Fc receptor bearing cells (monocytes, macrophages, NK cells) through binding to Fc region of IgG1, 2 and 4  PRTX - 100 has diverse acti

  9. Slide 9: Focused on Autoimmune Diseases: Huge Markets, Unmet Needs

    Focused on Autoimmune Diseases: Huge Markets, Unmet Needs  Millions suffer from autoimmune diseases, including: ▪ ITP - an orphan disease ▪ RA - the largest autoimmune market  Collectively, more than $23 billion spent annually on medications for RA and ITP worldwide 1  The leading biologic treatm

  10. Slide 10: Addresses Unmet Needs in the ITP and RA Markets

    PRTX - 100 Addresses Unmet Needs in the ITP and RA Markets 10  PRTX - 100 shown to be safe and well tolerated in humans; other ITP and RA drugs carry FDA black box warnings  PRTX - 100 reduces immune - mediated platelet destruction; the most recently approved therapies do not  Incumbent RA biolog

  11. Slide 11: Clinical Development Milestones

    Clinical Development Milestones 11 2012 2013 2014 2015 2016 2017 Immune Thrombocytopenia Explore Partnership Preclinical Rheumatoid Arthritis Phase 1b S. Africa Study 103 Phase 1b U.S. Study 104 Phase 2 EU Phase 1/2 Study 203 U.S. Phase 1/2 Study 202 Phase 1/2 Continuation Study Study 105 Additional

  12. Slide 12: Clinical Experience

    PRTX - 100: Clinical Experience Rheumatoid Arthritis (RA)  2005 – IND filed for RA  2006 – Phase 1 study completed  2007 – Second Phase 1 using PRTX - 100 with improved production/CMC processes  2010 - 2012 – Phase 1b RA Study (PRTX - 100 - 103) in South Africa; presented at ACR Annual Meeting i

  13. Slide 13: Immune Thrombocytopenia (ITP): A Rare and Serious Disorder

    Immune Thrombocytopenia (ITP): A Rare and Serious Disorder  Very low blood platelet count with increased risk of bleeding and bruising  Annual treatment cost of ~$60,000 for the most recently approved therapies  ITP is an autoimmune disease:  Afflicted people develop antibodies to their own plat

  14. Slide 14: Inhibits Platelet Phagocytosis

    PRTX - 100 Inhibits Platelet Phagocytosis  In vitro studies used monocytes and platelets isolated from human blood  Platelets were opsonized (coated with antibodies) and mixed with monocytes that had been treated with PRTX - 100 for 48 hours  Monocytes that were not pretreated with PRTX - 100 eng

  15. Slide 15: Effectively Treated Thrombocytopenia in a Murine Model of ITP

     Chow, et al. 2010 model — involves both cellular and humoral immunity  Thrombocytopenic SCID mice  Mice treated on day 8 after thrombocytopenia is established  PRTX - 100 raises platelet counts in a dose - dependent manner Semple , JW, et al. Poster presentation, American Society of Hematology

  16. Slide 16: Effectively Treated Thrombocytopenia in a Murine Model of ITP

    PRTX - 100 Effectively Treated Thrombocytopenia in a Murine Model of ITP 16  Thrombocytopenic SCID mice  Treatments (weekly) • No treatment ( Spl ) • IVIg (positive control) • PRTX - 100 250 µg/kg • PRTX - 100 25 µg/kg • PRTX - 100 2.5 µg/kg  PRTX - 100 treatment increased platelet counts in a do

  17. Slide 17: Study 202: Adult ITP Patients with Chronic, TPO-Refractory Disease (U.S.)

    Study 202: Adult ITP Patients with Chronic, TPO - Refractory Disease (U.S.) 17 PRTX - 100 1 µg/kg PRTX - 100 3 µg /kg PRTX - 100 6 µg PRTX - 100 12 µ/kg PRTX - 100 18 µg/kg Phase 1/2 study Primary objective: • Platelet response Secondary objectives: • Safety • Response characteristics, etc. PRTX - 1

  18. Slide 18: Study 203: Adult ITP Patients Who Failed One Prior Treatment (Europe)

    Study 203: Adult ITP Patients Who Failed One Prior Treatment (Europe) 18 Screening ≤ 21 days PRTX - 100 3 µg /kg PRTX - 100 6 µg PRTX - 100 12 µ/kg PRTX - 100 18 µg/kg Phase 1/2 study Primary objective: • Safety Secondary objectives: • Platelet response • Response duration, etc . PRTX - 100 24 µg/kg

  19. Slide 19: Study 104: Overall Safety in RA

    Study 104: Overall Safety in RA  Doses of 1.5 to 12 µg/kg PRTX - 100 were well tolerated, with no observed dose - limiting toxicities  No treatment - related SAEs and no requirement for expedited reports to FDA  Most commonly reported AEs were fatigue and flare of RA symptoms of mild to moderate

  20. Slide 20: Study 104: ACR50 Improvements in RA Patients on Background MTX Therapy

    ACR 5 0 Response Rate 0 5 10 15 20 25 30 35 0 29 57 85 MTX +/ - PRTX - 100  Trial PRTX - 100 - 104 (1 - 4): 41 patients w active RA randomized 3:1  Baseline MTX vs MTX + PRTX - 100, five weekly i.v. doses, 1.5, 3, 6, or 12 mcg/kg  Last PRTX - 100 dose at day 29  No drug - related SAEs 20 Percent

  21. Slide 21: Study 105: Continuation Study

    Study 105: Continuation Study  Enrollment commenced February, 2015; last dose/visit February 2016  Open - label, multiple fixed dose trial open to Study 104 participants who indicated a desire for additional treatment  Eleven patients enrolled; eight completed per protocol at single site  Primar

  22. Slide 22: Patents and Intellectual Property

    Patents and Intellectual Property  Patents (six issued in U.S., one in Japan, one in Europe) ▪ Initial U.S. patent 7,211,258, “Protein A compositions and methods of use” filed 2002 and issued with method of treatment claims for RA, juvenile RA, and systemic lupus erythematosus (SLE) ▪ U.S. continua

  23. Slide 23: Protalex Milestones

    Protalex Milestones x 2Q15 Complete Study 104 (U.S. Phase 1b in RA) x 2Q15 U.S. Orphan Drug Designation for PRTX - 100 in ITP x 4Q15 EU Orphan Drug Designation for PRTX - 100 in ITP x 4Q15 First dose in U.S. Phase 1/2 study (Study 202) of PRTX - 100 in ITP x 1Q16 First dose in EU Phase 1/2 study (St

  24. Slide 24: Key Investment Highlights

    Key Investment Highlights  PRTX - 100 ▪ Multiple clinical indications in both orphan and large markets (ITP, RA) ▪ Potentially applicable across a broad set of autoimmune diseases ▪ Considerable cost - of - goods advantage over competitors ▪ Demonstrates superior safety profile observed in six huma

  25. Slide 25: Financial Position

    Financial Position Ticker: PRTX Exchange: OTC >> Nasdaq Current market capitalization: ~$90 million Debt (converted in next offering): ~$17.5 million (Niobe Ventures) 25

  26. Slide 26: PRTX

    PRTX PROTALEA

Protalex — IPO Roadshow (July 2016) on 6ix